Effects of TRE on Body Weight
Primary
· Baseline to end of 12 week intervention
Measured as change in weight (kg).
| Group | Value | 95% CI |
|---|---|---|
| Standard of Care (SOC) | -1.68 | -2.59 – -0.77 |
| TRE + SOC | -4.59 | -5.51 – -3.67 |
Last reviewed · How we verify
NCT04916730
Effect of Time-restricted Eating on Catecholamine-sensitivity of Adipose Tissue in Obese Adults
Active, enrolled
NA
Results posted
Last updated 14 October 2025
What this trial tests
NA trial testing Standard of Care in Obesity in 61 participants. Participants enrolled and being followed up; not accepting new ones.
Timeline
17 December 2020
Primary endpoint
26 May 2023
26 May 2023
1 January 2026
Quick facts
| Lead sponsor | University of California, San Diego |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 61 |
| Start date | 17 December 2020 |
| Primary completion | 26 May 2023 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Standard of Care
- Time Restricted Eating
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
University of California, San Diego
Who can join
18 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Effects of TRE on Body Composition
Secondary
· Baseline to end of 12 week intervention
Measured as change in percent body fat.
| Group | Value | 95% CI |
|---|---|---|
| Standard of Care (SOC) | -0.8 | -1.82 – 0.22 |
| TRE + SOC | -1.3 | -2.15 – -0.50 |
Sponsor's own description
In a randomized controlled trial, the investigators intend to measure the health impact of time-restricted eating (TRE) in obese patients (body mass index (BMI) ≥ 30 kg/m2), who habitually eat for more than 14 hours every day. Patients will be randomly assigned to a control group of behavioral nutritional counseling (standard of care) or the intervention group of behavioral nutrition counseling with the addition of adopting a 10-hour eating window for 12 weeks (TRE).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Time-Restricted Eating Promotes Weight Loss and Favorable Changes in Adipose in Obesity: The TREAD Randomized Control Trial.
Wilkinson MJ, Padilla E, Wang Y, Raygani S, et al · · 2026 · PMID 42229885 · DOI 10.1002/oby.70228
Verify or expand the search:
- PubMed search for NCT04916730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard of Care
Trials testing the same drug.
- NCT07337655 — Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker · Phase 2, PHASE3 · not yet recruiting
- NCT07018466 — Tele-Exercise for MERP · NA · not yet recruiting
- NCT06930768 — Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers · NA · not yet recruiting
- NCT06918548 — Evaluating the Efficacy of NeoThelium FT in the Treatment of Pressure Injuries · NA · not yet recruiting
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
- NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
- NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
- NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
- NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04916730 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
- Last refreshed: 14 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04916730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing